Número 1 - EII al día

Enfermedad Inflamatoria Intestinal al día
BIBLIOGRAFÍA
1. Schaeffeler E, Fischer C, Brockmeier D, Wernet D, Moerike K,
Eichelbaum M, Zanger UM, Schwab M. Comprehensive analysis of
thiopurine S-methyltransferase phenotype-genotype correlation in a
large population of German-Caucasians and identification of novel
TPMT variants. Pharmacogenetics 2004;14:407-17.
2. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine
methyltransferase: possible mechanism for interaction with 6-mercaptopurine
and azathioprine. Br J Clin Pharmacol. 1995;39:456-9.
3. Lowry PW, Szumlanski CL, Weinshilboum RM, Sandborn WJ.
Balsalazide and azathiprine or 6-mercaptopurine: evidence for a
potentially serious drug interaction. Gastroenterology 1999;116:
1505-6.
4. Lewis LD, Benin A, Szumlanski CL, Otterness DM, Lennard L,
Weinshilboum RM, Nierenberg DW. Olsalazine and 6-mercaptopurine-related
bone marrow suppression: a possible drug-drug interaction.
Clin Pharmacol Ther. 1997;62:464-75.
5. Lowry PW, Franklin CL, Weaver AL, Szumlanski CL, Mays DC, Loftus
EV, Tremaine WJ, Lipsky JJ, Weinshilboum RM, Sandborn WJ.
Leucopenia resulting from a drug interaction between azathioprine or
6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide.
Gut 2001;49:656-64.
6. Dewit O, Vanheuverzwyn R, Desager JP, Horsmans Y. Interaction
between azathioprine and aminosalicylates: an in vivo study in
patients with Crohn's disease. Aliment Pharmacol Ther
2002;16:79-85.
7. Xin H, Fischer C, Schwab M, Klotz U. Effects of aminosalicylates on
thiopurine S-methyltransferase activity: an ex vivo study in patients
with inflammatory bowel disease. Aliment Pharmacol Ther
2005;21:1105-9.
39 • Enfermedad Inflamatoria Intestinal al día - Vol. 5 - Nº. 1 - 2006